Lymphocyte development, selection and education represent tightly controlled immune processes that normally prevent autoimmunity. Lymphocyte development likely induces cellular selection through apoptosis to remove potentially autoreactive cells. Dysregulated apoptosis, both interrupted as well as accelerated apoptosis, are now demonstrated as central defects in diverse murine autoimmune disease. In murine models of autoimmune lupus, mutations in cell death receptor Fas (CD95) and its ligand, FasL (CD95 L), have been identified. These errors create a lymphoid system resistant to apoptosis. In contrast, select lymphoid subpopulations of maturing autoimmune prone non-obese diabetic mice have identifiable and pathogenic T cells with both in vivo and in vitro heightened apoptosis after drug interventions. In part, these defects are due to faulty activation of transcription factors such as nuclear factor-B (NF-B) that normally protect against apoptotic death. The genetic basis of interrupted NF-B in pathogenic memory T cells in diabetes is attributable to a developmentally controlled gene defect in an essential subunit of the proteasome. No specific gene in most common forms of human autoimmune disease has yet been identified. Functional assays from diverse laboratories repeatedly demonstrate heightened apoptosis in multiple cellular signaling pathways for cell death, suggesting a common theme in disease causality.
The possible role of altered apoptosis in autoimmune diseases
Autoimmunity represents a diverse set of diseases defined clinically by the target organ destroyed. For the clinician, this is a straightforward observation with rheumatoid arthritis resulting from a presumed T cell attack of the joints, type I diabetes resulting from a presumed T cell attack against the insulin-secreting cells of pancreas, etc. Although the clinical manifestations for autoimmune diseases are distinct, the genetics are remarkably similar with a long-standing and common association of most autoimmune diseases with the human leukocyte antigen (HLA) region (also known as the major histocompatibility complex; MHC) as well as recent data confirming similar non-HLA gene region overlap (Becker et al. 1998) .
Apoptosis could play a role in autoimmune disease under two different guises. First, controlled regulation of cell death is a normal part of T cell selection and T cell education. Interruption of this process could lead to autoreactive cells. Second, cell death could represent a lymphocyteindependent mechanism causing cells in certain organs to die prematurely. To date, the majority of data, as well as identified genetic defects in accelerated or defective apoptosis, have most often defined autoimmunity with respect to abnormal T cell selection and development. In type I diabetes, possible target cell apoptotic defects in the pancreatic islets have been proposed, especially related to the Fas death receptor (Chervonsky et al. 1997 , Itoh et al. 1997 , Amrani et al. 1999 , Suarez-Pinzon et al. 1999 . However, more recent research has found contradictory data and alternative explanations that may reinterpret some of the data concerning linkage to heightened apoptosis in the islet target (Kang et al. 1997 , 1998 , Kim et al.1999b , 2000 , Pakala et al. 1999 , Thomas et al. 1999 , Restifo 2000 . This review article will thus focus on the role of apoptosis and autoimmunity as it relates to defects in apoptosis important for education of the lymphoid system.
One type of apoptotic defect in autoimmunity is the failure of autoreactive cells during development or during life to properly undergo negative selection. As a result, these cells fail to die. These severe defects in apoptosis in humans and mice result in autoreactivity as well as severe lymphoproliferation. An early identified example of this sort of 'failure to die' defect or failure to select out autoreactive cells were autoimmune defects in the molecules critical for directly inducing death. One such example is the Fas protein, a cell surface molecule also known as CD95 that belongs to the tumor necrosis factor (TNF) receptor (TNF-R)/ nerve growth factor receptor superfamily. A spontaneous mutation in Fas is carried by the lupus-like model of lpr/lpr mice, in which defective apoptosis leads to symptoms of lymphoproliferation and generalized autoimmunity (WatanabeFukunaga et al. 1992 , Watson et al. 1992 , Mountz et al. 1996 . Similarly, gld/gld lupus-like autoimmune mice with almost identical symptomatology carry a point mutation in the intracellular apoptotic domain of FasL (Allen et al. 1990 , Lynch et al. 1994 , Ramsdell et al. 1994 , Takahashi et al. 1994 . The identification of these autoimmuneassociated apoptotic defects in the Fas signal cascade stimulated a similar search to identify humans with lupus (systemic lupus erythematosis) with defects. Only a rare form of lupus has autoimmunity with diffuse lymphoproliferation and an identifiable mutation in the FasL gene (Wu et al. 1996a) . Humans with the rare Canala-Smith syndrome and autoimmune lymphoproliferative syndrome also possess a Fas mutation (RieuxLaucat et al. 1995 , Drappa et al. 1996 . Not unexpectedly, the lymphoproliferation characteristics of the lpr/lpr, gld/gld and these two human syndromes are suggestive of defective apoptosis and the failure to kill select lymphocytes. The majority of lupus patients appear not to have FasL mutations and, in fact, in a reciprocal fashion have reported accelerated lymphocytic apoptosis in vitro and increased FasL expression (Emlen et al. 1994 , Mysler et al. 1994 , Desai-Mehta et al. 1996 , Koshy et al. 1996 , Wu et al. 1996a , Kovacs et al. 1997 , Lorenz et al. 1997 , Wong et al. 1999 .
For most spontaneous forms of human and murine autoimmunity, massive lymphoproliferation is not a prominent feature of the disease. In fact, the data from our laboratory have uncovered the opposite defect in pathogenic cells, accelerated in vitro apoptosis. For example, the non-obese diabetic (NOD) mouse, an animal model of spontaneous type I diabetes (also known as insulin-dependent diabetes mellitus or juvenile-onset diabetes), has accelerated TNF--induced lymphocyte apoptosis in vitro due to a defective activation of nuclear factor-B (NF-B), which protects from TNF--induced cell death (Hayashi & Faustman 1999) . Similarly, in diverse human lupus studies, peripheral blood lymphocytes have accelerated in vitro apoptosis, decreased protective NF-B activation to protect cells from TNF--induced apoptosis, and increased expression of cell death receptors such as Fas. The genetic basis of these human defects is unknown.
Genetic risk factors for type I diabetes located in the MHC region of the genome
Type I diabetes mellitus is an autoimmune disease with genetic risk factors that map to the MHC region of the genome. In both human type I diabetes and two rodent models (NOD mouse and BB rat), pancreatic cells are selectively destroyed by a chronic autoimmune reaction ( Fig. 1) (Crisa et al. 1992 , Rabinovitch & Skyler 1998 . The MHC region contains immune response genes that are important in T cell education and in antigen presentation by both MHC class I and class II molecules. Studies of both humans and rodents have implicated the centrally located MHC class II genes as a major statistical risk factor for autoimmune disease. A clear functional derangement in MHC class II genes has been less clear. In contrast, cellular derangements in maturation markers, cytokine secretion or antigen presentation functions are commonly observed in NOD and diabetic humans and can be depicted by decreased expression of cell maturation antigens such as CD45 or altered levels of conformationally correct MHC class I and self-peptide complexes (Faustman et al. 1989 , Fu et al. 1993 , Smerdon et al. 1993 , Jansen et al. 1995 , Li et al. 1995 . Evidence based on functional assays suggests that human autoimmune diseases may be associated with impairment of antigen processing controlled by the MHC. Thus, cytosolic extracts of lymphocytes from humans with type I diabetes or NOD mice exhibit altered patterns of cleavage of test substrates by the proteasome, resulting in the generation of peptides that are poorly suited to assembly with MHC class I molecules (Faustman et al. 1989 , Fu et al. 1993 , Smerdon et al. 1993 , Jansen et al. 1995 , Li et al. 1995 . Furthermore, individuals with diverse autoimmune diseases, including type I diabetes, multiple sclerosis, and rheumatoid arthritis, exhibit decreased expression of peptide-loaded MHC class I molecules on the surface of their lymphocytes (Faustman et al. 1991 , Fu et al. 1993 , Li et al. 1995 . Moreover, clinical studies have shown that the antigen-presentation defect correlates with disease expression in identical twins with type I diabetes (Faustman et al. 1991) . The genes responsible for these peptide-processing defects are likely associated with human autoimmune diseases and map to the MHC region of the genome, suggesting that a similar MHC region abnormality might underlie these various conditions.
The MHC in humans and rodents contains many candidate genes, including those encoding the TAP (transporters associated with antigen processing) peptide transporters and LMP (low molecular weight protein) proteasome subunits that, when malfunctioning, might be responsible for impaired assembly of peptide-loaded MHC class I molecules. Thus, for example, both LMP2 and LMP7 are encoded by genes located in the MHC region of the genome (Fig. 2) ; these proteins are constitutively expressed in most cell types, but their expression is markedly increased in antigenpresenting cells (APCs) or lymphoid cells by interferon (IFN)-treatment (Fruh et al. 1992 , Van Kaer et al. 1994 , Hisamatsu et al. 1996 , Griffin et al. 1998 . Furthermore, these genes, since their discovery, have been strong candidates with high risk for development of type I diabetes, not only because of their chromosomal location but also transgenic mice with ablation of these genes have abnormal T cell selection and autoreactivity against transplants of syngeneic normal tissues (Aldrich Figure 2 Diagram of one point mutation in the shared promotor/enhancer region of LMP2 and TAP1. The NOD mutation creates a CAAT box in the shared promoter/enhancer region of LMP2/TAP1. CAAT box binding proteins likely act as negative regulators for transcriptional expression. The mRNA expression of LMP2 and TAP1 are significantly down-regulated in splenocytes derived from NOD female mice with type I diabetes.
et al. 1994 , Glas et al. 1994 , Van Kaer et al. 1994 , Wakatsuki et al. 1994 . Indeed, it is widely accepted that perhaps one of the first pathologic signs of tissue-specific autoimmunity is up-regulation of MHC class I on the tissue, even prior to lymphocyte invasion. This discordance between poorly educated T cells in the context of reciprocal future target tissue could be envisioned for all tissue-specific disease.
Ubiquitin-dependent proteolysis by the proteasome plays an essential role in various important cellular processes, including cell cycle progression, gene transcription, and signal transduction (Goldberg 1995 , Coux et al. 1996 . In many instances, the target protein is marked for degradation or processing by both phosphorylation and ubiquitination. Cleavage of endogenous proteins by the proteasome also generates small self-peptide fragments that contribute to T cell education after presentation by MHC class I molecules. Although, in general, the proteasome exhibits minimal variability in substrate selectivity and subunit composition, incorporation of the LMP2 and LMP7 subunits during assembly of the proteasome changes its specificity for self-proteins in such a manner that the suitability of the generated peptides for presentation in the peptidebinding groove of MHC class I molecules is increased (Belich et al. 1994 , Gaczynska et al. 1996 (Fig. 3B) . Expression of the LMP2 mRNA and protein is down-regulated in lymphocytes derived from NOD mice (Fig. 2) (Yan et al. 1997) , therefore explaining the altered T cell education towards self. Furthermore, LMP2 levels are almost undetectable in dendritic cells, certainly contributing towards defective antigen presentation of self-peptide (Poligone et al. 2002) .
The NOD mouse: a spontaneous mouse model of type I diabetes
Type I diabetes is usually caused by T cellmediated autoimmunity, with a prediabetic state characterized by the production of autoantibodies specific for proteins expressed by pancreatic cells (Fig. 1) . In general, the autoantibodies recognize intercellular islet proteins and likely form as bystander immune responses after islet death. Diabetes mellitus in humans is a genetically and clinically heterogeneous group of glucoseintolerance syndromes. Type 1 diabetes usually has an autoimmune T cell-mediated etiology in which the prediabetic state is characterized by development of autoantibodies against certain proteins expressed by the pancreatic cell, including insulin. A frequently used rodent model is the NOD mouse. The etiology of type I diabetes in the NOD mouse is both complex and multifactorial (Delovitch & Singh 1997 , Leiter & Atkinson 1998 , Rabinovitch 1998 . Both CD4+ and CD8+ T cells constitute the effector arm, with underlying functional defects in bone marrow-derived APCs, shown to be essential components in selection/ activation of the autoimmune repertoire. Many CD4+ and CD8+ T cell lines and clones with diabetogenic potential against a variety of identified and unidentified antigens have been established from both islets and spleen. Destruction of pancreatic cells apparently entails both necrotic and apoptotic events in response to invasion of the islets by leukocytes (called insulitis) (Rabinovitch 1998) . Although insulitis is not observed in NOD mice up to 3-8 weeks of age, it is detected with increasing incidence in both female and male animals after 8-12 weeks of age or older. A clear sex difference is observed with respect to the onset of diabetes (Fig. 1) . In NOD females, the actual onset of diabetes is observed at approximately 20 weeks of age, and the number of animals developing overt diabetes increases with age (Makino et al. 1980) (Fig. 1) . The cumulative incidence of diabetes by the age of 30 weeks in NOD females is 70-80% although highly variable per colony (Makino et al. 1980) (Fig. 1C) . By contrast, in the case of NOD males, the onset of diabetes is observed to begin at around 20 weeks of age, and the number of animals affected by the age of 30 weeks is only about 20% (Makino et al. 1980) (Fig. 1C) . There are large numbers of leukocytes in the insulin infiltrates of NOD mice, histologically suggesting lymph node formation around islets (Fig. 1) . One of the strain-specific peculiarities of NOD mice is the accumulation of many T cells in peripheral lymphoid organs, pancreas and submandibular salivary glands. This T lymphocyte accumulation possibly reflects low interleukin (IL)-2 levels and the resistance of thymocytes and peripheral T cells to the induction of apoptosis.
Furthermore, apoptotic resistance may be an early phenotype of lymphoid lineages prior to disease initiation (Lamhamedi-Cherradi et al. 1998) .
A survey of the NOD literature shows that many, if not most, compounds and treatments have a positive effect on the progression to diabetes in the NOD mouse if administered during a very early time, up to approximately 5-6 weeks of age (Table  1) . NOD female mice with minimal or no sign of disease from birth to roughly 5 weeks of age are highly amenable to diverse cures. At approximately 12 weeks of age, lymphocytes migrate into the islet-containing regions of the pancreas and accumulate in layers around and within the islets. At this stage of prediabetes most treatments of the NOD mouse are no longer efficacious. The actual onset of disease, defined clinically as hyperglycemia, is typically after 20 weeks of age. Until recently, no treatments other than bone marrow transplantation showed efficacy at the late stages of diabetes. Table 1 indicates, for each therapy, the approximate NOD age and disease state where the various treatments have a positive or negative effect on the eventual disease development or late-stage disease reversal.
The NOD mouse, like the diabetic human, is a model of type I diabetes with a strong genetic component that maps to the MHC genomic region of the genome. A specific proteasome defect has now been identified in NOD mouse lymphocytes that results from down-regulation of expression of the proteasome subunit LMP2, which is encoded by a gene in the MHC genomic region in T cells (Hayashi & Faustman 1999) (Figs 2 and 3 ). This defect begins to subtly appear after 8 weeks of age and in certain T cells prevents the proteolytic processing required for the production and activation of NF-B. This plays important roles in immune and inflammatory responses, as well as increases the susceptibility of the affected cells to apoptosis induced by TNF- (Fig. 4) . NF-B activation pathways are known to be cell specific, i.e. dendritic cells have very low LMP2 but intact NF-B (Poligone et al. 2002) . The proteasome and its MHC-encoded subunits thus play a new role as protector from apoptosis. The proteasome dysfunction is both tissue and developmental stage specific and likely contributes to disease pathogenesis in the lymphocytes and possible tissue targeting by reciprocal hyper-expression defects (Hayashi & Faustman 1999) . 
Activation of NF-B by the proteasome processing pathway: apoptosis signal pathways and proteins involved in autoimmunity
The proteasome also plays an important role in the processing and activation of the transcription factor NF-B/Rel superfamily (family of structurally related protein subunits of NF-B), which are sequestered in the cytoplasm as a result of their association with the I B family (Baldwin 1996) (Fig. 4) . Previously, it was thought that the entire proteasome structure and all of its contained subunits were required for NF-B activation (Fig. 4) . Additionally, the inducible MHC-linked proteasome units, LMP2 and LMP7, were obligatory for MHC class I display, although they were expressed constitutively as well as at low levels (Fig. 4) . The highly inducible LMP2 and LMP7 subunits were known to be obligatory only for the processing of other protein substrates.
NF-B is activated in response to various extracellular stimuli, including IL-1, lipopolysaccharide, and TNF- (Thanos & Maniatis 1995 , Verma et al. 1995 , Baeuerle & Baltimore 1996 , Baldwin 1996 . Activated NF-B, in turn, has been implicated in the regulation of gene transcription that contributes to cytokine generation, expression of cell surface adhesion epitopes, lymphocyte maturation, protection from TNF--induced apoptosis, and antigen processing and presentation by MHC class I molecules (Bohnline et al. 1988 , Cross et al. 1989 , Tan et al. 1992 , Beg & Baltimore 1996 , Van Antwerp et al. 1996 . Insights into the various biological functions of NF-B have been obtained by the generation of knockout mice lacking either subunits of this protein or associated regulatory proteins (Burkly et al. 1995 , Kontgen et al. 1995 , Weih et al. 1995 , Franzoso et al. 1997 , Bushdid et al. 1998 , Caamano et al. 1998 , Kanegae et al. 1998 , Hu et al. 1999 , Li et al. 1999a ,b, Takeda et al. 1999 .
Active NF-B exists predominantly as a heterodimer composed of p65 (RelA) and either p50 or p52 subunits. The p50 and p52 subunits are generated constitutively but are significantly augmented by certain stimuli such as IL-1 and TNF-. The proteasome mediates removal of the carboxy termini of the p105 and p100 precursors respectively (Fan & Maniatis 1991 , Schmid et al. 1991 , Palombella et al. 1994 , Coux & Goldberg 1998 , Lin et al. 1998 , Sears et al. 1998 , and this proteasome cleavage is obligatory for the active p65-p50 subunit (Fig. 4) . In the cytoplasm of resting cells, NF-B is associated with the inhibitory protein I B (Ghosh & Baltimore 1990 , Hayashi et al. 1993a . Cell stimulation results in the phosphorylation of I B by the I B kinase (IKK) complex and its degradation by the ubiquitin-proteasome pathway, thereby allowing the p50-p65 or p52-p65 heterodimers to translocate to the nucleus and initiate the transcription of target genes (Ghosh & Baltimore 1990 , Neri et al. 1991 , Palombella et al. 1994 , MacKichan et al. 1996 , Belich et al. 1999 (Fig. 4) . Complexes of p65 with p105 have also been detected, but these do not appear to translocate rapidly to the nucleus in response to cell stimulation (Lin et al. 1970 , Sun et al. 1994 .
Although increased or decreased apoptosis can be considered as a primary or secondary feature of Treatment is detrimental (−); treatment has therapeutic benefit (+); treatment cures (+++); treatment has no effect (0).
the autoimmune diseases, the TNF-R superfamily appears central for these autoimmune disease processes. The TNF-R superfamily represents molecules with extracellular domains consisting of cysteine-rich motifs, a transmembrane region and an intra-cytoplasmic tail. The structure and molecular cloning of the TNF-R superfamily is described elsewhere and is beyond the scope of this review (Liang & Fesik 1997 , Wallach et al. 1999 . For instance NF-B, which is activated to protect from TNF--induced apoptosis, significantly induces Fas-mediated cell death (Ouaaz et al. 1999) . Additionally, NF-B activation in response to TNF-may contribute to FasL expression (Hsu et al. 1999) . The evolving basic science observations of overlapping apoptotic pathways are likely to explain why, in autoimmune disease, the apoptotic defects can confer phenotypes of accelerated as well as reduced T cell selection.
Figure 4
The figure depicts an antigen-presenting cell and the central role of the proteasome with expressed LMP2 subunits in two important biochemical pathways that may be involved in type I diabetes. The LMP2-containing proteasome plays an established role in preparing self-peptides for MHC class I presentation and education to self. The LMP2 proteasome is also obligatory for NF-B activation. NF-B is essential for lymphocyte maturation, apoptosis protection and cytokine balances. The lymphoid cells from NOD mice after 6 weeks of age stop production of LMP2 protein, thus conferring the two documented phenotypes and biochemical derangements in both antigen presentation and protection from apoptosis (I B, Inhibitor of NF-B). 
The role of the proteasome in T cell education, NF-B activation and apoptosis
Type I diabetes is caused by T cell-mediated autoimmunity against the pancreatic cell. The pathologic picture, characteristic of both the human and the NOD mouse, is that of T cells surrounding and invading the islets, which show a hyper-expression of MHC class I proteins early in this inflammatory process. The prediabetic state is characterized clinically by the production of autoantibodies specific for proteins expressed by pancreatic cells. Human type I diabetes and the NOD mouse show a strong genetic component that maps to the MHC region of the genome. Recently, a specific defect has been found in the composition of the proteasome in lymphocytes from NOD mice which results from down-regulated expression of the LMP2 subunit, whose gene is encoded in the MHC region (Fig. 2) . This defect in LMP2 expression in the NOD mouse is due, in part, to a specific mutation in the promoter (Fig. 2) . The defective LMP2 expression interrupts both generation of self-peptides necessary for the development of T cell tolerance to self-antigens (Yan et al. 1997) and activation of NF-B (Hayashi & Faustman 1999). NF-B is a protein critical for T cell maturation and for normal immune and inflammatory responses (Hayashi & Faustman 1999) . The proteasome dysfunction is specific both with regard to cell lineage and developmental stage, and is likely to contribute fundamentally to disease pathogenesis (Hayashi & Faustman 1999) .
Our laboratory has sought to understand why, in type I diabetes, the T cells treat the insulinsecreting cells as a foreign invader. We have therefore attempted to understand the process of T cell education to self-antigens, and how this is altered in type 1 diabetes. T cell education requires self-antigen presentation, which is typically provided by 'professional' APCs, i.e. macrophages, dendritic cells and B cells. A commonly held notion is that autoimmunity results when T cells become inappropriately activated, e.g. through stimulation by antigens cross-reactive with self-antigens; typically viewed as an MHC class II defect. A recent report presented evidence that pointed to a completely novel basis for autoreactivity, and then provided evidence for an interruption in the presentation of self-antigens, in both diabetic humans as well as NOD mice (Yan et al. 1997) . Based on these studies, we proposed that MHC class I self-peptide display was a pathway essential for normal tolerance, an idea that at the time represented a considerable departure from the then accepted view of MHC class I function, namely the presentation of peptide derived from foreign intracellular proteins (especially viral proteins) for the generation of cytotoxic T cells. During the period from 1993 to 1995, studies in mice in which the genes encoding essential chaperone proteins for MHC class I intracellular assembly were deleted, confirmed an important role for MHC class I self-peptide display in the process of T cell education to self-antigens (Aldrich et al. 1994 , Glas et al. 1994 , Van Kaer et al. 1994 .
Our subsequent studies concerned the basis for defective MHC class I self-peptide presentation in the NOD mouse and uncovered an alteration in the MHC region of the genome involving the gene encoding an IFN -inducible proteasome subunit known as LMP2. The proteasome is a multisubunit ATP-dependent protease, one of whose functions is the degradation of intracellular antigens for presentation in the MHC class I protein complex. Prior to this time it was not appreciated that the proteasome and MHC had a linked role in apoptosis protection. The proteasome is relatively constant except for several subunits, specifically LMP2, LMP7 and LMP10, whose expression is induced upon activation of APCs by inflammatory cytokines, e.g. IFN-. Previous research findings showed that the induction of the LMP2 subunit of the catalytic proteasome is defective in the NOD mouse. This, in turn, interrupts antigen presentation due to defects both in transcription and perhaps translation (Yan et al. 1997) (Fig. 2) . Furthermore, our most recent data has shown that this defect in LMP2 protein expression not only prevents the effective generation of self-peptides for MHC class I display, but also interrupts the proteolytic processing of NF-B, as well as the degradation of the inhibitory I B subunit (Hayashi & Faustman 1999) .
This proteasome defect reduces the generation of active NF-B, which regulates lymphocytic maturation, normal regulation of T cell proinflammatory and cytokine production and protection of T cells from TNF--induced apoptosis (Hayashi & Faustman 1999) . A recent study in NOD mice documented a turn-off of LMP2 protein production in select lymphoid lineage cells after 10 weeks of age (Hayashi & Faustman 1999) . This event interrupts both the presentation of self-peptides by the APCs as well as normal T cell development, two phenotypes we had previously established as characteristic of both murine and human autoimmune diabetes, and is thus probably an essential trigger for disease initiation. The turn-on of MHC class I in islets that occurs early in the process of islet invasion by T cells probably augments self-antigen display. This would promote a vigorous cytotoxic T cell attack, initiated by the poorly educated, maldeveloped LMP2-deficient T cells and/or the defective antigen presenter cells. The defective proteasome function of APCs, which is not shared by the insulin-secreting cell, may help to define the target selection of autoreactive T cells due to the contrasting development of the two lineages of cells. The novel aspect of the LMP2 defect is that the NOD proteasome identifies a single gene locus that simultaneously interrupts self-antigen presentation that is necessary to establish T cell tolerance and interrupt NF-B generation. The defective NF-B activation is confined only to those lymphoid lineage cells that lack effective LMP2 protein expression. These studies established for the first time that MHClinked genes such as LMP2 can have a direct role in T cell development and apoptosis. The substrate specificity of the large multi-subunit proteasome could be altered in regard to its regulatory degradative functions (as in NF-B activation) on the basis of regulated changes in protease subunit composition. Diabetic humans, similar to diabetic NOD mice, likely have defective antigen presentation, defective proteasome processing of test substrates in vitro and interrupted MHC class I display of self-peptides with poor T cell selection (Faustman et al. 1991) . Recent findings define and present the data supporting the central interruption of the proteasome and TNF--induced apoptosis in the NOD mouse (Ryu et al. 2001) .
Increased sensitivity of NOD mouse lymphocytes to TNF--induced apoptosis
Evidence indicates that NF-B is an important protector from apoptosis (Beg et al. 1995) . The hepatic apoptosis observed in embryos of p65, IKK or IKK knockout mice appears to result from the associated defects in NF-B activation (Beg & Baltimore 1996 , Li et al. 1999b . The activation of NF-B by the ubiquitin-proteasome pathway is thought to protect cells from TNF--induced cell death (Beg & Baltimore 1996 , Van Antwerp et al. 1996 , Wang et al. 1996b , Wu et al. 1996b (Fig. 4) . Thus, inhibition of the nuclear translocation of NF-B enhances the apoptotic effect of TNF-. The anti-apoptotic effect of NF-B is likely mediated by the activation of genes that encode survival proteins.
We have investigated the effect of TNF-on the viability of NOD mouse lymphocytes in which TNF--induced activation of NF-B is impaired. Whereas incubation of BALB/c splenocytes with various concentrations (2-20 ng/ml) of TNF-for 24 h had virtually no effect on cell survival, TNFinduced a dose-dependent decrease in the survival of splenocytes derived from male or female NOD mice (Hayashi & Faustman 1999) . Similarly, whereas incubation of BALB/c splenocytes with TNF-at 10 ng/ml for up to 48 h had no effect on cell viability, the survival of NOD splenocytes was already markedly reduced after incubation with the same concentration of TNF-for only 12 h (Hayashi & Faustman 1999) . The toxic effect of TNF-on NOD mouse lymphocytes also appeared more pronounced for female than for male animals. Exposure of lymphocytes from LMP2 knockout mice to TNF-also resulted in marked cell death (Hayashi & Faustman 1999) . Analysis of DNA fragmentation by agarose gel electrophoresis confirmed that TNF-induced a pattern of inter-nucleosomal fragmentation characteristic of apoptosis in lymphocytes from NOD mice and LMP2 knockout mice, whereas it did not induce DNA fragmentation in those from BALB/c mice (Hayashi & Faustman 1999) . Thus, it is likely that the toxicity of TNF-for NOD mouse lymphocytes is attributable to the proteasome-associated defect in NF-B activation in these cells. A diagramatic model for TNF-induced apoptosis is depicted in Fig. 6 . TNF-also reduced the viability of spleen cells derived from 7-day-old NOD mice, but to a lesser extent than it did in cells derived from adult animals; the cytokine had no effect on the viability of spleen cells derived from 7-day-old BALB/c mice. Whereas TNF-had no effect on the viability of cultured macrophages derived from 13·5-day BALB/c or NOD mouse fetal liver, it induced a dose-and time-dependent decrease in the viability of such cells derived from the LMP2 knockout mouse fetal liver at the same stage of development (Hayashi & Faustman 1999) . Similarly, TNF-had no effect on the viability of cultured BALB/c or NOD mouse embryonic fibroblasts, whereas TNF-treatment of such cells derived from LMP2 knockout mice resulted in prominent cell death (Hayashi & Faustman 1999 , 2000 . Although disruption of the NF-B p65, IKK or IKK genes is associated with marked abnormalities in liver development (Beg et al. 1995 , Beg & Baltimore 1996 , Li et al. 1999b , Rudolph et al. 2000 , hematoxylin-eosin staining of liver sections from 6-week-old NOD mice did not reveal any apparent liver defects (Hayashi & Faustman 1999) .
Impaired granulocyte-macrophage colony formation by NOD mouse spleen cells NF-B also plays an important role in the maturation of lymphocytes and monocytes. We therefore examined the development of the granulocyte-macrophage cell lineage in splenocytes isolated from 6-week-old NOD and BALB/c mice. Colony-formation assays revealed that, whereas granulocyte-macrophage colony-stimulating factor (GM-CSF) induced the formation of clusters of mature granulocytes-macrophages in BALB/c mouse splenocytes, the formation of such clusters was impaired in splenocytes from NOD mice (Fig. 5A-D) . Furthermore, whereas exposure of GM-CSF-treated spleen cell cultures from BALB/c mice to TNF-had no effect on cell viability or colony development, TNF-induced the death of all cells in the NOD mouse cultures (Fig. 5E-H) .
The specificity of the developmental defect and cytotoxic effect of TNF-in the granulocytemacrophage lineage of NOD mice was investigated by examining colony-forming units of erythrocytes in cultures of spleen cells derived from 6-week-old BALB/c and NOD animals. Erythrocyte colony formation appeared normal in erythropoietinsupplemented cultures of NOD mouse spleen cells, compared with that observed in spleen cells from BALB/c mice (Hayashi & Faustman 1999) . Moreover, TNF-had no effect on erythrocyte colony formation, which is known to require NF-B, in spleen cells from either BALB/c or NOD mice. These results suggest that a lack of NF-B activation in granulocyte-macrophage precursors derived from NOD mice at 6 weeks of age impairs the maturation of these cells and renders them susceptible to the cytotoxic effect of TNF-. In contrast, NF-B appears to be functional in the erythrocyte lineage of these mice, which appears to develop normally and to be resistant to TNF--induced apoptosis. Given that TNF-had no effect on the viability of cultured macrophages derived from the 13·5-day BALB/c or NOD mouse fetal liver, the proteasome defect in these animals appears to be both cell type and developmental stage specific.
Gender/age-related and tissue-specific proteasome dysfunction and disease expression
The incidence of diabetes is markedly greater in NOD females than in NOD males. Most human autoimmune diseases are also preferentially expressed in females. Consistent with a role for defective proteasome, accelerated apoptosis and NF-B function in NOD mouse diabetes, the cytosolic extracts of splenocytes from male NOD mice were able to convert a small proportion of recombinant p105 to p50, albeit an aberrantly sized protein fragment (Hayashi & Faustman 1999) . Splenocyte extracts from female animals did not generate any detectable p50 protein in this assay (Hayashi & Faustman 1999) . Furthermore, both the time-course and dose-response relation for the effect of TNF-on cell viability revealed that the sensitivity of splenocytes from NOD females to this cytokine was greater than that of cells from NOD males (Hayashi & Faustman 1999) . The characteristics of knockout mice that lack Rel family proteins or LMP2 show partial overlap with those of NOD mice (Van Kaer et al. 1994 , Burkly et al. 1995 , Kontgen et al. 1995 , Weih et al. 1995 , Horwitz et al. 1997 . However, LMP2-deficient mice do not develop diabetes by 32 weeks of age (D L Faustman, unpublished observation), consistent with the contribution of multiple chromosomal regions to disease penetrance in both NOD mice and humans. The homogeneous nature of the gene defect in all tissues of LMP2 knockout mice differs from the apparent developmental stage and tissue specificity of the proteasome defect in NOD mice, which might underlie target selection in disease expression. LMP2-deficient and other knockout mice with defects in the assembly of MHC class I molecules with self-peptides destroy transplanted syngeneic tissues from control animals (Li & Faustman 1993 , Vidal-Puig & Faustman 1994 , Freland et al. 1998 . Target cell loss might thus result from preferential direct attack by cytotoxic T lymphocytes in the early stages of autoimmune disease.
The marked pro-apoptotic effect of TNF-in NOD mouse lymphocytes might also indicate a role for this cytokine in early cell destruction in these animals. Such a mechanism of cell death would require that the cells exhibit the same proteasome defect as that of NOD mouse lymphocytes, characterized by loss of LMP2 expression, aberrant NF-B activation, increased sensitivity to the cytotoxic effect of TNF-, and reduced expression of peptide-filled MHC class I molecules on the cell surface. However, one of the early pathological features of autoimmune diabetes in both humans and rodent models is hyperexpression of correctly assembled MHC class I molecules on the surface of cells (Foulis 1987 , Ono et al. 1988 , Weringer & Like 1988 , Hanafusa et al. 1990 , Kay et al. 1991 , Vives-Pi et al. 1996 , Stephens et al. 1997 , a phenomenon that requires intact proteasome function. Studies of both humans and animals with diabetes or other autoimmune diseases suggest that discordance in the regulation of MHC-linked genes between tissues might confer target specificity for attack by cytotoxic T lymphocytes (Hayashi & Faustman 1999) .
Macrophages and fibroblasts derived from 13·5-day NOD mouse embryos exhibited normal cell growth and resistance to TNF-cytotoxicity. In contrast, TNF-induced a marked proapoptotic effect in the corresponding cell types derived from LMP2 knockout mice (Hayashi & Faustman 1999 , 2000 . TNF-also induced a relatively small decrease in the viability of spleen cells derived from 7-day-old NOD mice, but had no such effect on corresponding cells from BALB/c mice. In contrast, lymphoid cells of splenic origin, lung macrophages (Kupffer cells), and granulocytes-macrophages from 6-to 8-week-old NOD mice exhibited reduced LMP2 expression, impaired NF-B activation, and increased sensitivity to the cytotoxic effect of TNF- (Hayashi & Faustman 1999) . Furthermore, consistent with a role for the proteasome and NF-B in normal cell growth, cultures of spleen cells from 6-week-old NOD mice with GM-CSF failed to induce normal expansion of the granulocyte-macrophage cell lineage. Recently, the islets of Langerhans, liver, and erythrocytes of 6-to 8-week-old NOD mice appeared normal. The ability of NOD mouse macrophages to activate regulatory T cells in an autologous mixed lymphocyte reaction has also been shown to be impaired (Atkinson & Leiter 1999) .
The age-dependent proteasome defect in the macrophages of NOD mice likely explains some of the important features of disease development in these animals. Thus, NOD mice show no signs of autoimmunity at ages up to 3 weeks. At 5 weeks and older, insulitis begins to appear, and by 8 weeks of age autoantibodies are detectable. The insulitis gradually increases in intensity, with complete destruction of islets usually apparent by 30 weeks of age (Makino et al. 1980) . Furthermore, the outcomes of various interventions and treatments in NOD mice are age dependent (Table 1) . For instance, the administration of TNF-to animals older than 6 weeks has been shown to sometimes prevent the development of diabetes, whereas the same treatment in animals younger than 4 weeks has no effect or a detrimental effect (Yang et al. 1994b) . Therefore, both the time-course of histopathology of autoreactivity and the paradoxical age-dependent responses to TNF-treatment parallel the altered developmental regulation of LMP2 expression and NF-B activity in these animals.
Defective proteasome function and autoimmunity
The ubiquitin-proteasome pathway plays an essential role in many important biological processes (Maniatis 1999) . Protein degradation by this pathway thus generates peptides for presentation by MHC class I molecules and either activates or inactivates transcription factors. In general, the proteasome subunits vary minimally among eukaryotic cells. The IFN--induced expression of the MHC-encoded proteasome subunits LMP2 and LMP7 is thought to promote the generation of endogenous peptides compatible with the peptidebinding cleft of MHC class I molecules (Akiyama et al. 1994 , Belich et al. 1994 . The MHC-encoded proteasome subunits also play a role in general proteasome function, including the processing and activation of NF-B.
The defect in proteasome function in NOD mouse splenocytes is attributable to a loss of expression of the proteasome LMP2 subunit, and is evident from the impaired proteolytic processing of the p105 precursor of the NF-B subunit p50 in vitro as well as from the lack of degradation of phosphorylated I B in these cells in response to TNF-. This defect confers sensitivity on the affected cells to the apoptotic effect of TNF-. The role of LMP2 in NF-B activation was confirmed by the observations that cytosolic extracts of lymphocytes from LMP2 knockout mice also failed to convert p105 to p50, and that only NOD mouse tissues that lack LMP2 protein showed impaired activation of NF-B and sensitivity to TNF--induced apoptosis (Hayashi & Faustman 1999 , 2000 . The recent findings indicate that the defect in LMP2 protein production in NOD mice is both developmental stage (age) and tissue specific. Thus, NOD macrophages and fibroblasts from 13·5-day embryos show normal levels of LMP2 expression and are resistant to the cytotoxic effect of TNF-. In contrast, splenocytes, granulocytesmacrophages, and lung Kupffer cells from 6-to 8-week-old NOD mice lack LMP2 protein, exhibit defective activation of NF-B, or are sensitive to TNF--induced cell death. Islet cells, erythrocytes, and liver cells of adult NOD mice do not exhibit the LMP2 defect. Thus, NOD mouse islets express LMP2 protein and do not exhibit increased sensitivity to TNF--induced apoptosis (Hayashi & Faustman 1999) . Dysfunction of a gene in the MHC region of the genome thus virtually abolishes the activity of a transcription factor that plays important roles in both immune and non-immune cellular functions. The NOD mouse thus represents a newly defined mosaic model of discordant MHC gene expression that exhibits marked proteasome dysfunction in an age-and tissue-specific manner. The delayed maturation of lymphocytes and cytokine abnormalities apparent in NOD mice that spontaneously develop type I diabetes are mirrored, in part, by the clinical phenotypes of knockout mice lacking NF-B subunits or LMP2 (Van Kaer et al. 1994 , Sha et al. 1995 , Beg & Baltimore 1996 , Snapper et al. 1996 , Franzoso et al. 1997 , Horwitz et al. 1997 , Iotsova et al. 1997 , Caamano et al. 1998 , Tanaka et al. 1999 . The clinical relevance of the phenotypes of the NOD mouse and of these various knockout animals to human disease is supported by the existence of nearly identical cytokine and lymphocyte maturation defects in humans with type I diabetes (Van Kaer et al. 1994 , Sha et al. 1995 , Beg & Baltimore 1996 , Snapper et al. 1996 , Franzoso et al. 1997 , Horwitz et al. 1997 , Iotsova et al. 1997 , Caamano et al. 1998 , Tanaka et al. 1999 (Fig. 6 ).
In conclusion, these research findings have demonstrated the existence of a marked defect in proteasome function in lymphocytes from autoimmune diabetes-prone NOD mice. This dysfunction results from a lack of the LMP2 subunit, which is encoded by a gene located in the MHC region of the genome, and it results in both impaired processing of self-peptides for presentation by MHC class I molecules as well as the inability to activate NF-B. A similar age-related defect in granulocytes-macrophages is proposed to confer target specificity in autoimmunity towards tissues with intact expression. Abnormal processing of intracellular proteins thus may contribute to the pathogenesis of type I diabetes. On a therapeutic front, the purposeful application of induced apoptosis in end-stage adult NOD mice permanently reversed the diabetes (Ryu et al. 2001) . Apoptotic sensitive cells, at least in the NOD, are disease-causing cells identifiable in the late stages of disease.
Figure 6
A model for TNF--induced apoptosis of NOD lymphocytes. Depicted is a possible mechanism to describe TNF--induced apoptosis of NOD lymphocytes. The TNF-signaling pathway leads to an unknown pro-apoptotic signal. Defective NF-B activator causes the inactivation of gene expression for anti-apoptotic factors. As a result, survival mechanisms are not activated. This leads to time-and dose-dependent decreases in cell survival.
(AZA) on the onset of diabetes mellitus in NOD mice. 
